Amgen puts its KRAS hopes on ‘Navy Seals’ team of drug hunters
Amgen's never moved faster. In late August of last year, the first patient enrolled in...
Amgen's never moved faster. In late August of last year, the first patient enrolled in...
It’s not surprising that Steven Yatomi-Clarke started his second career at a company named Prescient...
The nation's youngest cancer patients have been given new hope, with a cutting-edge treatment being...
Over the last decade, technological improvements and algorithmic learning have made rapid improvements to many...
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of...
On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of...
Highlights: Innovative ‘basket’ study design will assess drug in multiple cancers Precision medicine approach offers...
Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.